MEDIA CONTACT

media@libd.org

Resources

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

• Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia. • The new collaboration further expands Boehringer Ingelheim’s circuitry-based approach […]

LIBD in the News: NPR’s All Things Considered

LIBD in the News: NPR’s All Things Considered

The full story from Jon Hamilton aired September 24, 2020. 

Upcoming Events